Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
Q9P0N9
UPID:
TBCD7_HUMAN
Alternative names:
Cell migration-inducing protein 23
Alternative UPACC:
Q9P0N9; E7EV96; Q2TU37; Q53F44; Q5SZL7; Q86VM8; Q96MB8
Background:
TBC1 domain family member 7 (TBC1D7) is a pivotal component of the TSC-TBC complex, alongside TSC1-TSC2, with a crucial role in regulating the mTORC1 signaling cascade. This complex exhibits GTPase-activating protein (GAP) activity towards RHEB, a direct activator of mTORC1, thereby acting as a negative regulator in response to cellular growth conditions. TBC1D7's involvement in sensing growth factors and glucose highlights its integral role in cellular metabolism and growth regulation.
Therapeutic significance:
TBC1D7's association with Macrocephaly/megalencephaly syndrome, an autosomal recessive disorder, underscores its clinical relevance. Understanding the role of TBC1D7 could open doors to potential therapeutic strategies for treating this syndrome, which is characterized by abnormal brain enlargement, intellectual disability, and skeletal muscle underdevelopment.